
BTSG Stock Forecast & Price Target
BTSG Analyst Ratings
Bulls say
BrightSpring Health Services Inc. has demonstrated robust performance, particularly within its OP Rehab segment, which is growing in the double digits and maintaining attractive margins. The Pharmacy Solutions segment reported a 43% year-over-year increase in specialty revenue, reaching approximately $2.6 billion in 2025, with management projecting further margin improvements and substantial EBITDA growth driven by strategic M&A. Additionally, the Provider division is benefiting from stable reimbursement rates and increased demand, evidenced by a 15% year-over-year growth in home health average daily census in 4Q:25, further enhancing the company’s position in the healthcare market.
Bears say
BrightSpring Health's stock outlook is negatively influenced by the potential for reduced client budgets, which may adversely impact both the company's business and revenue generation. Furthermore, the reliance on prescription utilization and the potential decline in healthcare professionals prescribing certain therapies present additional risks that could negatively affect revenues and cash flows. Additionally, BrightSpring Health's substantial debt load may restrict its capacity for growth investments, further complicating its operational strategies amidst a competitive market landscape.
This aggregate rating is based on analysts' research of BrightSpring Health Services Inc and is not a guaranteed prediction by Public.com or investment advice.
BTSG Analyst Forecast & Price Prediction
Start investing in BTSG
Order type
Buy in
Order amount
Est. shares
0 shares